Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes

被引:94
作者
Bondanza, A
Valtolina, V
Magnani, Z
Ponzoni, M
Fleischhauer, K
Bonyhadi, M
Traversari, C
Sanvito, F
Toma, S
Radrizzani, M
La Seta-Catamancio, S
Ciceri, F
Bordignon, C
Bonini, C
机构
[1] Univ Vita Salute San Raffaele, Canc Immunotherapy & Gene Therapy Program, Expt Hematol Lab,S Raffaele Sci Inst, DIBIT3A1, I-20132 Milan, Italy
[2] Molmed SpA, Milan, Italy
[3] Xcyte Therapies, Seattle, WA USA
关键词
D O I
10.1182/blood-2005-09-3716
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In allogeneic hematopoietic cell transplantation (allo-HCT), the immune recognition of host antigens by donor T lymphocytes leads to a beneficial graft-versus-leukemia (GvL) effect as well as to life-threatening graft-versus-host disease (GvHD). Genetic modification of T lymphocytes with a retroviral vector (RV) expressing the herpes simplex virus-thymidine kinase (TK) suicide gene confers selective sensitivity to the prodrug ganciclovir (GCV). In patients, the infusion of TK+ lymphocytes and the subsequent administration of GCV resulted in a time-wise modulation of antihost reactivity for a GvL effect, while controlling GvHD. Because activation required for genetic modification with RV may reduce antihost reactivity, we investigated the requirements for maximizing the potency of human TK+ lymphocytes. Whereas T-cell receptor triggering alone led to effector memory (EM) TK+ lymphocytes, the addition of CD28 costimulation through cell-sized beads resulted in the generation of central memory (CM) TK+ lymphocytes. In a quantitative model for GvHD using nonobese diabetic/severely combined immunodeficient mice, CM TK+ lymphocytes were more potent than EM TK+ lymphocytes. GCV administration efficiently controlled GvHD induced by CM TK+ lymphocytes. These results warrant the clinical investigation of CM suicide gene-modified human T lymphocytes for safe and effective allo-HCT.
引用
收藏
页码:1828 / 1836
页数:9
相关论文
共 57 条
  • [1] Memory CD4+ T cells do not induce graft-versus-host disease
    Anderson, BE
    McNiff, J
    Yan, J
    Doyle, H
    Mamula, M
    Shlomchik, MJ
    Shlomchik, WD
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (01) : 101 - 108
  • [2] Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation:: a phase 1/2 study
    André-Schmutz, I
    Le Deist, F
    Hacein-Bey-Abina, S
    Vitetta, E
    Schindler, J
    Chedeville, G
    Vilmer, E
    Fischer, A
    Cavazzana-Calvo, M
    [J]. LANCET, 2002, 360 (9327) : 130 - 137
  • [3] Haematopoietic cell transplantation as immunotherapy
    Appelbaum, FR
    [J]. NATURE, 2001, 411 (6835) : 385 - 389
  • [4] CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy
    Berger, C
    Blau, CA
    Clackson, T
    Riddell, SR
    Heimfeld, S
    [J]. BLOOD, 2003, 101 (02) : 476 - 484
  • [5] Patterns of engraftment in different strains of immunodeficient mice reconstituted with human peripheral blood lymphocytes
    Berney, T
    Molano, RD
    Pileggi, A
    Cattan, P
    Li, H
    Ricordi, C
    Inverardi, L
    [J]. TRANSPLANTATION, 2001, 72 (01) : 133 - 140
  • [6] Bondanza A, 2005, METH MOLEC MED, V109, P475
  • [7] Safety of retroviral gene marking with a truncated NGF receptor
    Bonini, C
    Grez, M
    Traversari, C
    Ciceri, F
    Marktel, S
    Ferrari, G
    Dinauer, M
    Sadat, M
    Aiuti, A
    Deola, S
    Radrizzani, M
    Hagenbeek, A
    Apperley, J
    Ebeling, S
    Martens, A
    Kolb, HJ
    Weber, M
    Lotti, F
    Grande, A
    Weissinger, E
    Bueren, JA
    Lamana, M
    Falkenburg, JHF
    Heemskerk, MHM
    Austin, T
    Kornblau, S
    Marini, F
    Benati, C
    Magnani, Z
    Cazzaniga, S
    Toma, S
    Gallo-Stampino, C
    Introna, M
    Slavin, S
    Greenberg, PD
    Bregni, M
    Mavilio, F
    Bordignon, C
    [J]. NATURE MEDICINE, 2003, 9 (04) : 367 - 369
  • [8] HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
    Bonini, C
    Ferrari, G
    Verzeletti, S
    Servida, P
    Zappone, E
    Ruggieri, L
    Ponzoni, M
    Rossini, S
    Mavilio, F
    Traversari, C
    Bordignon, C
    [J]. SCIENCE, 1997, 276 (5319) : 1719 - 1724
  • [9] Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15
    Brentjens, RJ
    Latouche, JB
    Santos, E
    Marti, F
    Gong, MC
    Lyddane, C
    King, PD
    Larson, S
    Weiss, M
    Rivière, I
    Sadelain, M
    [J]. NATURE MEDICINE, 2003, 9 (03) : 279 - 286
  • [10] Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence
    Cavalieri, S
    Cazzaniga, S
    Geuna, M
    Magnani, Z
    Bordignon, C
    Naldini, L
    Bonini, C
    [J]. BLOOD, 2003, 102 (02) : 497 - 505